Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders

Gastroenterology Clinics of North America

Volumn 46, Issue 1, 2017, Pages 103-120

  Ghoshal, Uday C ^a   Ghoshal, Ujjala ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gut microbiota; Hydrogen breath tests; Malabsorption syndrome; Rifaximin; Tropical sprue

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; METRONIDAZOLE; NEOMYCIN; NITROIMIDAZOLE; NORFLOXACIN; QUINOLONE DERIVATIVE; RIFAXIMIN; TEGASEROD; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIUM CULTURE; BACTEROIDES; COLONY FORMING UNIT; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC ACCURACY; DIGESTIVE TRACT ENDOSCOPY; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GASTRIC HYPOACIDITY; GASTROINTESTINAL MOTILITY; GOLD STANDARD; HUMAN; HYDROGEN BREATH TEST; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE INFECTION; IRRITABLE COLON; LOW DRUG DOSE; MALABSORPTION; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RECURRENT INFECTION; REVIEW; RISK FACTOR; RUMINOCOCCACEAE; SACCHAROMYCES BOULARDII; SENSITIVITY AND SPECIFICITY; SMALL INTESTINAL BACTERIAL OVERGROWTH; STAPHYLOCOCCUS AUREUS; SYMPTOMATOLOGY; TREATMENT DURATION; BACTERIUM; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PATHOPHYSIOLOGY; SMALL INTESTINE;

ANTI-BACTERIAL AGENTS; BACTERIA; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINE, SMALL;

EID: 85011277056     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.09.008     Document Type: Review

References (85)

1. 1 Mackie, R.I., Sghir, A., Gaskins, H.R., Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 69 (1999), 1035S–1045S.
2. 2 Prakash, S., Rodes, L., Coussa-Charley, M., et al. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 5 (2011), 71–86.
3. 3 Gabrielli, M., D'Angelo, G., Di Rienzo, T., et al. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci 17:Suppl 2 (2013), 30–35.
4. 4 Ghoshal, U.C., Srivastava, D., Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 20 (2014), 2482–2491.
5. 5 Nagao-Kitamoto, H., Kitamoto, S., Kuffa, P., et al. Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest Res 14 (2016), 127–138.
6. 6 Ghoshal, U.C., Srivastava, D., Ghoshal, U., et al. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 26 (2014), 753–760.
7. 7 Khoshini, R., Dai, S.C., Lezcano, S., et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53 (2008), 1443–1454.
8. 8 Ghoshal, U.C., Srivastava, D., Misra, A., et al. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol 28 (2016), 281–289.
9. 9 Grace, E., Shaw, C., Whelan, K., et al. Review article: small intestinal bacterial overgrowth–prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38 (2013), 674–688.
10. 10 Sachdev, A.H., Pimentel, M., Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 4 (2013), 223–231.
11. 11 Ghoshal, U.C., Shukla, R., Ghoshal, U., et al. The gut microbiota and irritable bowel syndrome: friend or foe?. Int J Inflam, 2012, 2012, 151085.
12. 12 Ghoshal, U.C., Kumar, S., Mehrotra, M., et al. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil 16 (2010), 40–46.
13. 13 Ghoshal, U.C., Mehrotra, M., Kumar, S., et al. Spectrum of malabsorption syndrome among adults & factors differentiating celiac disease & tropical malabsorption. Indian J Med Res 136 (2012), 451–459.
14. 14 Ghoshal, U., Ghoshal, U.C., Ranjan, P., et al. Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. BMC Gastroenterol, 3, 2003, 9.
15. 15 Stotzer, P.O., Bjornsson, E.S., Abrahamsson, H., Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scand J Gastroenterol 31 (1996), 875–880.
16. 16 Ghoshal, U.C., Ghoshal, U., Das, K., et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol 25 (2006), 6–10.
17. 17 Husebye, E., The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 51:Suppl 1 (2005), 1–22.
18. 18 Pimentel, M., Soffer, E.E., Chow, E.J., et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 47 (2002), 2639–2643.
19. 19 Vantrappen, G., Janssens, J., Hellemans, J., et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest 59 (1977), 1158–1166.
20. 20 Pimentel, M., Morales, W., Lezcano, S., et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y) 5 (2009), 435–442.
21. 21 Ghoshal, U.C., Kumar, S., Misra, A., et al. Pathogenesis of tropical sprue: a pilot study of antroduodenal manometry, duodenocaecal transit time & fat-induced ileal brake. Indian J Med Res 137 (2013), 63–72.
22. 22 Ghoshal, U.C., Ghoshal, U., Ayyagari, A., et al. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time. J Gastroenterol Hepatol 18 (2003), 540–547.
23. 23 Cook, G.C., Delayed small-intestinal transit in tropical malabsorption. Br Med J 2 (1978), 238–240.
24. 24 Barboza, J.L., Okun, M.S., Moshiree, B., The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opin Pharmacother 16 (2015), 2449–2464.
25. 25 Akesson, A., Akesson, B., Gustafson, T., et al. Gastrointestinal function in patients with progressive systemic sclerosis. Clin Rheumatol 4 (1985), 441–448.
26. 26 Bharadwaj, S., Tandon, P., Gohel, T., et al. Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. J Clin Gastroenterol 49 (2015), 559–564.
27. 27 Lyford, G., Foxx-Orenstein, A., Chronic Intestinal Pseudoobstruction. Curr Treat Options Gastroenterol 7 (2004), 317–325.
28. 28 Marie, I., Ducrotte, P., Denis, P., et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 48 (2009), 1314–1319.
29. 29 Miller, L.J., Small intestinal manifestations of diabetes mellitus. Yale J Biol Med 56 (1983), 189–193.
30. 30 Nakamura, K., Sakuragi, N., Takakuwa, A., et al. Paneth cell alpha-defensins and enteric microbiota in health and disease. Biosci Microbiota Food Health 35 (2016), 57–67.
31. 31 Ghosh, D., Porter, E., Shen, B., et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3 (2002), 583–590.
32. 32 Salzman, N.H., Ghosh, D., Huttner, K.M., et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422 (2003), 522–526.
33. 33 Ghoshal, U.C., Goel, A., Ghoshal, U., et al. Chronic diarrhea and malabsorption due to hypogammaglobulinemia: a report on twelve patients. Indian J Gastroenterol 30 (2011), 170–174.
34. 34 Rubio-Tapia, A., Hernandez-Calleros, J., Trinidad-Hernandez, S., et al. Clinical characteristics of a group of adults with nodular lymphoid hyperplasia: a single center experience. World J Gastroenterol 12 (2006), 1945–1948.
35. 35 Smith, G.M., Chesner, I.M., Asquith, P., et al. Small intestinal bacterial overgrowth in patients with chronic lymphocytic leukaemia. J Clin Pathol 43 (1990), 57–59.
36. 36 Ghoshal, U.C., Ghoshal, U., Jain, M., et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 17 (2002), 1331–1333.
37. 37 Lombardo, L., Foti, M., Ruggia, O., et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 8 (2010), 504–508.
38. 38 Fried, M., Siegrist, H., Frei, R., et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35 (1994), 23–26.
39. 39 Lo, W.K., Chan, W.W., Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 11 (2013), 483–490.
40. 40 Mathias, J.R., Clench, M.H., Review: pathophysiology of diarrhea caused by bacterial overgrowth of the small intestine. Am J Med Sci 289 (1985), 243–248.
41. 41 Pimentel, M., Kong, Y., Park, S., IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci 49 (2004), 84–87.
42. 42 Savage, D.C., Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31 (1977), 107–133.
43. 43 Bouhnik, Y., Alain, S., Attar, A., et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 94 (1999), 1327–1331.
44. 44 Sachdev, A.H., Pimentel, M., Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14 (2012), 439–445.
45. 45 Posserud, I., Stotzer, P.O., Bjornsson, E.S., et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56 (2007), 802–808.
46. 46 Bala, L., Ghoshal, U.C., Ghoshal, U., et al. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn Reson Med 56 (2006), 738–744.
47. 47 Riordan, S.M., McIver, C.J., Thomas, D.H., et al. Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 32 (1997), 556–563.
48. 48 Srivastava, D., Ghoshal, U., Mittal, R.D., et al. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil 26 (2014), 1408–1416.
49. 49 Al-Khatib, K., Lin, H.C., Immune activation and gut microbes in irritable bowel syndrome. Gut Liver 3 (2009), 14–19.
50. 50 Kumar, S., Ghoshal, U.C., Jayalakshmi, K., et al. Abnormal small intestinal permeability in patients with idiopathic malabsorption in tropics (tropical sprue) does not change even after successful treatment. Dig Dis Sci 56 (2011), 161–169.
51. 51 Ghoshal, U.C., Park, H., Gwee, K.A., Bugs and irritable bowel syndrome: The good, the bad and the ugly. J Gastroenterol Hepatol 25 (2007), 244–251.
52. 52 Lykova, E.A., Bondarenko, V.M., Parfenov, A.I., et al. Bacterial overgrowth syndrome in the small intestine: pathogenesis, clinical significance and therapy tactics. Eksp Klin Gastroenterol(6), 2005, 51–57 113. [in Russian].
53. 53 Camilo, E., Zimmerman, J., Mason, J.B., et al. Folate synthesized by bacteria in the human upper small intestine is assimilated by the host. Gastroenterology 110 (1996), 991–998.
54. 54 Pimentel, M., Wallace, D., Hallegua, D., et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 63 (2004), 450–452.
55. 55 Choung, R.S., Ruff, K.C., Malhotra, A., et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 33 (2011), 1059–1067.
56. 56 Majewski, M., McCallum, R.W., Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 52 (2007), 139–142.
57. 57 Reddymasu, S.C., Sostarich, S., McCallum, R.W., Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?. BMC Gastroenterol, 10, 2010, 23.
58. 58 Vandeputte, D., Falony, G., Vieira-Silva, S., et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 65 (2016), 57–62.
59. 59 Gabbard, S.L., Lacy, B.E., Levine, G.M., et al. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci 59 (2014), 638–644.
60. 60 Sung, H.J., Paik, C.N., Chung, W.C., et al. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy Patients. J Neurogastroenterol Motil 21 (2015), 545–551.
61. 61 Tursi, A., Brandimarte, G., Giorgetti, G., High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 98 (2003), 839–843.
62. 62 Chang, M.S., Green, P.H., A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease. Therap Adv Gastroenterol 5 (2012), 31–36.
63. 63 Ghoshal, U.C., How to interpret hydrogen breath tests. J Neurogastroenterol Motil 17 (2011), 312–317.
64. 64 Pimentel, M., Chow, E.J., Lin, H.C., Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95 (2000), 3503–3506.
65. 65 Lu, C.L., Chen, C.Y., Chang, F.Y., et al. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study. Clin Sci (lond) 95 (1998), 165–169.
66. 66 Yu, D., Cheeseman, F., Vanner, S., Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 60 (2011), 334–340.
67. 67 Erdogan, A., Rao, S.S., Gulley, D., et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 27 (2015), 481–489.
68. 68 Ning, Y., Lou, C., Huang, Z., et al. Clinical value of radionuclide small intestine transit time measurement combined with lactulose hydrogen breath test for the diagnosis of bacterial overgrowth in irritable bowel syndrome. Hell J Nucl Med 19:2 (2016), 124–129.
69. 69 Zhao, J., Zheng, X., Chu, H., et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil 26 (2014), 794–802.
70. 70 Schatz, R.A., Zhang, Q., Lodhia, N., et al. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol 21 (2015), 4574–4582.
71. 71 Berthold, H.K., Schober, P., Scheurlen, C., et al. Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. J Gastroenterol 44 (2009), 944–951.
72. 72 DuPont, H.L., Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc 90 (2015), 1116–1124.
73. 73 Pistiki, A., Galani, I., Pyleris, E., et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents 43 (2014), 236–241.
74. 74 Pimentel, M., Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 43:Suppl 1 (2016), 37–49.
75. 75 Barbara, G., Feinle-Bisset, C., Ghoshal, U.C., et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology 150 (2016), 1305–1318.
76. 76 Lauritano, E.C., Gabrielli, M., Lupascu, A., et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 22 (2005), 31–35.
77. 77 Pimentel, M., Lembo, A., Chey, W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364 (2011), 22–32.
78. 78 Lauritano, E.C., Gabrielli, M., Scarpellini, E., et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 13 (2009), 111–116.
79. 79 Di Stefano, M., Malservisi, S., Veneto, G., et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 14 (2000), 551–556.
80. 80 Furnari, M., Parodi, A., Gemignani, L., et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 32 (2010), 1000–1006.
81. 81 Rosania, R., Giorgio, F., Principi, M., et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol 8 (2013), 169–172.
82. 82 Attar, A., Flourie, B., Rambaud, J.C., et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117 (1999), 794–797.
83. 83 Deng, Y., Misselwitz, B., Dai, N., et al. Lactose intolerance in adults: biological mechanism and dietary management. Nutrients 7 (2015), 8020–8035.
84. 84 Lauritano, E.C., Gabrielli, M., Scarpellini, E., et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 103 (2008), 2031–2035.
85. 85 Scarpellini, E., Gabrielli, M., Lauritano, C.E., et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 25 (2007), 781–786.